Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials-Reference-Cited by-同舟云学术

Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials

Published:2016-08 Issue: Volume:178 Page:135-144
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Ridker Paul M.,Amarenco Pierre,Brunell Robert,Glynn Robert J.,Jukema J. Wouter,Kastelein John J.P.,Koenig Wolfgang,Nissen Steven,Revkin James,Santos Raul D.,Schwartz Pamela F.,Yunis Carla,Tardif Jean-Claude

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference38 articles.

1. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Baigent;Lancet,2010

2. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials;Mihaylova;Lancet,2012

3. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein;Ridker;N Engl J Med,2008

4. Ezetimibe added to statin therapy after acute coronary syndromes;Cannon;N Engl J Med,2015

5. A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction;N Engl J Med,2008

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody;CPT: Pharmacometrics & Systems Pharmacology;2023-11-22

2. Anti-drug Antibody Magnitude and Clinical Relevance Using Signal to Noise (S/N): Bococizumab Case Study;The AAPS Journal;2023-09-02

3. PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology;Cancers;2023-02-22

4. Current evidence on the role of lipid lowering drugs in the treatment of psoriasis;Frontiers in Medicine;2022-08-11

5. The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia;Cureus;2022-06-03